Pfizer is a research-based biopharmaceutical global company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer's diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical includes the primary care, specialty care, established products, emerging markets and oncology customer-focused units. Diversified includes animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. The Company's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol), Lyrica (pregabalin, for neuropathic pain/fibromyalgia), Diflucan (fluconazole, an oral antifungal medication), Zithromax (azithromycin, an antibiotic), Viagra (sildenafil, for erectile dysfunction) and Celebrex/Celebra (celecoxib, an anti-inflammatory drug).

Company Growth (employees)
Type
Public
HQ
New York, US
Founded
1848
Size (employees)
96,500 (est)
Website
pfizer.com
Pfizer was founded in 1848 and is headquartered in New York, US

Key People/Management at Pfizer

Ian C. Read

Ian C. Read

Chairman & CEO
Frank A. D'Amelio

Frank A. D'Amelio

EVP, CFO & Business Operations
Laurie J. Olson

Laurie J. Olson

EVP of Strategy, Portfolio and Commercial Operations
Chuck Hill

Chuck Hill

Executive Vice President, Worldwide Human Resources
Rady Johnson

Rady Johnson

Executive VP, Chief Compliance And Risk Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research & Development
Doug Lankler

Doug Lankler

Executive VP, General Counsel
Freda C. Lewis-Hall

Freda C. Lewis-Hall

EVP & Chief Medical Officer

Pfizer Office Locations

Pfizer has offices in New York, Buenos Aires, Bentley, Shanghai and in 37 other locations
New York, US (HQ)
235 East 42nd Street
Show all (42)

Pfizer Financials and Metrics

Pfizer Financials

Pfizer's revenue was reported to be $52.8 b in FY, 2016
USD

Revenue (Q2, 2017)

12.9 b

Market capitalization (13-Nov-2017)

213.2 b
Pfizer's current market capitalization is $213.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

51.6 b49.6 b48.9 b52.8 b

Revenue growth, %

(4%)(2%)8%

Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017

Revenue

12.6 b11.4 b12.8 b12.4 b10.9 b11.9 b12.1 b12.9 b

Cost of goods sold

2.3 b2 b2.5 b2.4 b1.8 b

Gross profit

10.4 b9.3 b10.3 b10 b9 b

Gross profit Margin, %

82%82%81%81%83%
USDY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2 b10.1 b2.2 b3.3 b3.6 b

Inventories

6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b

PP&E

12.4 b11.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017

Cash

2.1 b2.9 b3.4 b2.4 b3.6 b3.7 b3.1 b

Inventories

6.5 b6.1 b6.2 b6.4 b5.8 b5.8 b7.6 b7.6 b

Current Assets

59.5 b57.8 b58.3 b57 b49.4 b51.7 b45 b38.5 b41.3 b43.8 b35.9 b36.4 b

PP&E

12.4 b12.3 b12.2 b12 b11.5 b11.4 b13.7 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b

Accounts Receivable

940 m148 m21 m(134 m)

Inventories

(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b

Depreciation and Amortization

3.1 b

Cash From Operating Activities

4.8 b

Purchases of PP&E

(806 m)
USDY, 2017

Revenue/Employee

133.6 k

Financial Leverage

2.9 x
Show all financial metrics

Pfizer Operating Metrics

Y, 2014Y, 2015Y, 2016

Active Clinical Studies

448338

Phase III Trials

223034

Discovery Projects

919096

Drugs Approved by FDA

1
Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
MedivationAugust 22, 2016$14 b
Anacor PharmaceuticalsJune 24, 2016$5.2 b
AllerganNovember 23, 2015$160 b

Pfizer Market Value History

Pfizer Revenue Breakdown

Pfizer Median Salaries

Source: 241 public H-1B filings from Pfizer

Pfizer's Web-traffic and Trends

Pfizer Online and Social Media Presence

Pfizer News and Updates

How BioSTL developed a 20-year plan to boost St. Louis’ biotech industry

St. Louis’ current position as a global leader in plant science and biotech didn’t happen overnight. Instead, careful planning over the course of two decades laid the foundation for the booming startup ecosystem in St. Louis that we all enjoy today. EQ got a chance to catch up with Maggie Crane, com…

Osteoarthritis Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Osteoarthritis Treatment Market report is segmented by therapy, by product type, by end users, and by regions - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Astellas joins crowd of pharmas under investigation for copay charity donations

Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs. In a legal filing, the drugmaker disclosed a federal subpoena for information about its contributions, as part of a joint criminal and civil investiga…

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts win NICE recommendations

Pfizer’s Ibrance had a big head start on Novartis rival Kisqali in the U.S., but when it comes to England, new discount deals with cost-effectiveness watchdogs have the contenders on more equal footing.

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 (Reuters) - Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

Dietary Supplements Market 2017 Global Analysis, Opportunities and Forecast To 2022

Dietary Supplements Market 2017 Supply And Consumption Research Report 2022 Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Pfizer Company Life and Culture

You may also be interested in